Generic medicines are the therapeutic equivalents of original molecules which are no more covered by patent protection and which are manufactured following the same quality standards, complying with the same registration procedures of the Authorities.

Generic medicines are significantly less expensive than originators (-40%) and help to contain the medicines bill in France.

DCIPHARMA is acting in the growth dynamics of generics which benefit from the combination of generics promotion by the Authorities and the loss of patent protection of major molecules until 2008.